Savara Announces Change of Date for 2020 Annual Meeting of Stockholders

Meeting to Be Held on Friday, May 29, 2020 in Virtual-Only Format

AUSTIN, Texas--(BUSINESS WIRE)--May 8, 2020-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced a change in the date, time, and format of its 2020 Annual Meeting of Stockholders due to public health and safety concerns related to the COVID-19 pandemic and in the interest of the health and well-being of stockholders and other meeting participants. The Annual Meeting will now be held in a virtual-only format by means of a live audio webcast at 3:00 p.m. CDT on Friday, May 29, 2020, instead of the location, time, and date previously disclosed in the proxy materials filed with the Securities and Exchange Commission on April 15, 2020. Stockholders will not be able to attend the Annual Meeting in person.

As described in the proxy materials, all stockholders of record at the close of business on March 30, 2020, and those who hold a legal proxy, are entitled to participate in and vote at the Annual Meeting. Stockholders can attend the Annual Meeting by accessing and entering the 16-digit control number on the proxy card or notice of availability of proxy materials previously furnished. Guests may attend the Annual Meeting without a control number but will not be able to vote or ask questions.

All stockholders are encouraged to submit their vote by proxy in advance by one of the methods described in the proxy materials, even if they plan to attend the Annual Meeting. The proxy card previously furnished will not be updated to reflect the change in date, time, and location and may continue to be used to vote in connection with the Annual Meeting.

About Savara

Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis and cystic fibrosis-affected individuals. Apulmiq is an inhaled liposomal ciprofloxacin in Phase 3 development for non-cystic fibrosis bronchiectasis (NCFB). AeroVanc is an inhaled vancomycin in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Savara’s strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approval and commercialization. More information can be found at (Twitter: @SavaraPharma, LinkedIn:

Savara Inc. IR & PR
Anne Erickson (
(512) 851-1366

Source: Savara Inc.